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Nevertheless, that research line allowed us to study biochemical 
changes occurring, simultaneously, in GPi as well as in the ventral 
anterior thalamus (VA), the crucial structure conveying pallido-
fugal information to cortex, and in putamen (PUT). Indeed, it 
was possible to measure endogenous amino acids, collectible from 
extracellular space intra-GPi, intra-VA, and intra-PUT, before and 
during an efficacious DBS delivery (Fedele et al., 2001; Stefani et al., 
2005, 2006; Galati et al., 2006).
At first, at odd with traditional views, the administration of 
the dopamine agonist apomorphine, although clinically effica-
cious, failed to modify GABA and glutamate content in GPi. Also 
30–40 min STN-DBS (with clinically relevant parameters) barely 
affected GABA, taurine, aspartate, and glutamate concentrations 
(Fedele et al., 2001). On the other hand, STN-DBS had promoted 
the augmentation of the GPi [and substantia nigra pars reticu-
lata (SNr)] cGMP levels (Stefani et al., 2005; Galati et al., 2006). 
The implicit interpretation of these unexpected findings was that, 
instead of silencing STN-mediated transmission, DBS might dictate 
a clustered and increased discharge pattern in SNr. Those data were 
initially considered paradoxical, since in conflict, at least in part, 
with findings collected in rodent’s disease model. For instance, some 
IntroductIon
In early 2000s, it was proposed, asides from the traditional neuro-
surgery performed on a single target for severe Parkinson’s disease 
(PD) patients (commonly the subthalamic nucleus – STN – or 
the globus pallidus pars interna – GPi) the so-called “multi-target 
strategy,” consisting of simultaneous and bilateral implantation 
of multiple basal ganglia (BG) nuclei (Peppe et al., 2004; Stefani 
et al., 2009). In principle, our genuine purpose was to improve 
treatment of specific signs of clinical Parkinsonism, for example 
ensuring a more efficient control of involuntary movements. With 
this goal in mind, in a cohort of advanced PD patients afflicted by 
rather disabling dyskinesias, both STN and GPi were implanted 
bilaterally. As a consequence, it was possible to conclude that GPi-
DBS provided efficacious recovery from hypokinesia that was not 
significantly worse than STN-DBS (Peppe et al., 2004), years before 
recent comparative investigations (Follett et al., 2010).
However, the simultaneous switch-ON of both targets did not 
produce higher benefits than each target alone, neither on dys-
kinesia nor in the management of axial signs. Rather, the clinical 
indication for that sort of invasive – and costly – “double-targeting” 
approach tended to become less in time.
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Deep brain stimulation (DBS) of the subthalamic nucleus (STN), in Parkinson’s disease (PD) 
patients, is a well established therapeutic option, but its mechanisms of action are only partially 
known. In our previous study, the clinical transitions from OFF- to ON-state were not correlated 
with significant changes of GABA content inside GPi or substantia nigra reticulata. Here, 
biochemical effects of STN-DBS have been assessed in putamen (PUT), internal pallidus (GPi), 
and inside the antero-ventral thalamus (VA), the key station receiving pallidothalamic fibers. 
In 10 advanced PD patients undergoing surgery, microdialysis samples were collected before 
and during STN-DBS. cGMP , an index of glutamatergic transmission, was measured in GPi and 
PUT by radioimmunoassay, whereas GABA from VA was measured by HPLC. During clinically 
effective STN-DBS, we found a significant decrease in GABA extracellular concentrations in VA 
(−30%). Simultaneously, cGMP extracellular concentrations were enhanced in PUT (+200%) 
and GPi (+481%).  These findings support a thalamic dis-inhibition, in turn re-establishing a more 
physiological corticostriatal transmission, as the source of motor improvement.  They indirectly 
confirm the relevance of patterning (instead of mere changes of excitability) and suggest 
that a rigid interpretation of the standard model, at least when it indicates the hyperactive 
indirect pathway as key feature of hypokinetic signs, is unlikely to be correct. Finally, given 
the demonstration of a key role of VA in inducing clinical relief, locally administration of drugs 
modulating GABA transmission in thalamic nuclei could become an innovative therapeutic 
strategy.
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doi: 10.3389/fnsys.2011.00017rat studies showed the prevalent inhibition of SNr during STN-
DBS (Windels et al., 2003, 2005). These inconsistencies may reveal 
that the abrupt dopamine depletion by 6-OHDA, possibly for the 
overwhelming role of fast occurring compensatory mechanisms, is 
not fit to investigate properly the electrophysiological and chemical 
features that PD imposes.
If we consider the cGMP increase as an indirect estimation of 
neuronal activity in GPi during STN-DBS (Fedele and Raiteri, 
1999), our findings were in theoretical accord with the STN-DBS-
mediated excitation and clustering of the GPi firing pattern as 
observed in MPTP primates (Hashimoto et al., 2003).
Yet, the relevance of the cGMP finding, per se, was uncertain; 
after all, it depends on an acute change of the NMDA-NO endog-
enous transmission (notoriously impaired in extrapyramidal dis-
orders, but not exactly a routine therapeutic target!).
Is it feasible that similar changes in cGMP levels are really cor-
related with consistent clinical amelioration in every PD patient?
How could we further deepen our knowledge on the biochemical 
counterparts of the OFF–ON behavioral transitions?
Do the observed changes in the first output stations (GPi/SNr) 
affect the motor thalamus, the crucial structure conveying motor 
information to cortex?
How STN-DBS influence intra thalamic GABA and, in turn, 
corticostriatal transmission?
Therefore, we investigated the extracellular GABA concentration 
in VA during the first delivery of STN-DBS (n = 10), at clinically 
relevant or null voltage. Simultaneously, in the same PD patients, 
the cGMP level was measured in GPi (n = 10) and PUT (n = 6).
In synthesis, our results will show that DBS reversibly reduces 
(−30%) VA GABA levels, increases cGMP levels in GPi and also 
significantly increases cGMP concentration in PUT, as far as the 
clinical transition to ON-state takes place.
Our findings sound in accord with the growing body of evidence 
refreshing and reforming the standard model of BG circuitry. The 
dogma about an hyperactive indirect pathway as a crucial hallmark 
of Parkinsonian hypokinetic signs, for instance, has been revisited 
since the relief from akinesia and rigidity occurs in the absence of 
reduced GPi excitability and changes of GPi GABA levels. However, 
clinical “ON-state” requires a rapid change in thalamic GABA con-
tent, as here described. Therefore, these results confirm, in line with 
older models, that VA is the core clinical player in determining 
thalamocortical transmission.
PatIents and Methods
Ten advanced PD patients (mean age = 57.6 ± 9.2 years; mean UPDRS 
score in OFF = 47.7 ± 8.1; mean disease duration = 11 ± 3.1 years) 
were included in this study according to selection criteria previously 
reported (Fedele et al., 2001; Stefani et al., 2006). Stimulating perma-
nent electrodes were implanted in both the STN and the GPi, bilater-
ally. For trajectory details, and implantation procedures, see Figure 1 
legend and References (Fedele et al., 2001; Stefani et al., 2005, 2006). 
Written, informed consent was obtained from each patient. The 
Local Ethics Committee approved the protocol and consent form 
describing the risks and potential benefits of the study. At time for 
surgery, every patient was under washout (at least overnight with-
drawal from l-DOPA and 3-day suspension of dopamine-agonists).
Probes were infused with sterile PBS (5 μL/min) for stabiliza-
tion (90 min). Then, basal microdialysis samples (50 μL each) and 
clinical data were collected for 50 min. Afterward, STN-DBS was 
switched on for 60 min (n = 10 patients, Table 1 and Figure 2). 
Stimulation parameters were: 90 μs, 130 Hz and mean 2.4 V (but 
see Figure 1 legend). After 60 min DBS, 60 min of recovery were 
performed. All procedures were without additional risks for the 
patient, since guide tubes for micro-recordings were already placed 
in each target (STN and GPi).
Clinical changes were assessed utilizing selected items of UPDRS 
(rigidity 0–4, finger tapping 0–4, hand movement 0–4; total = 0 
corresponds to “normal,” 12 maximum score) by a neurologist blind 
to the stimulus intensity between 0 and 3 V. GABA and cGMP were 
determined by HPLC and by RIA, respectively.
Significance of GABA and cGMP changes was assessed by com-
paring the mean of the concentrations obtained in the single 
fractions under basal conditions with those during STN-DBS 
and during recovery conditions. Mean values were compared by 
ANOVA two way (first main factor: treatment with three levels: 
basal, treatment, recovery; second main factor: time with six lev-
els) corrected by Greenhouse–Geisser correction and followed by 
post hoc Scheffè test to assess the significance of the differences 
between single fractions. Given the not demonstrated normal-
ity of biochemical data the results were also confirmed by non-
parametric Friedman ANOVA followed by Wilcoxon as post hoc 
test. Clinical scores were compared using similar non-parametric 
methods. Correlation were studied between the maximal changes 
induced by DBS in the GABA and cGMP concentrations (Pearson 
parametric  correlations)  and  clinical  score  (non-parametric 
Spearman correlations). The changes were evaluated as the maxi-
mum change of each of these parameters in comparison to their 
mean basal score.
results
clInIcal effect of dBs
For  all  the  fore-coming  biochemical  results  during  STN-DBS, 
consider that they correlate with a significant change of UPDRS 
(at least 30% amelioration of main examined motor features). To 
note, post hoc Wilcoxon test showed a significant UPDRS score 
amelioration from the first 10 min of DBS in comparison to all the 
basal score. Only in case of PUT cGMP, the statistical data compar-
ing biochemical and clinical scores did not reach significance (but 
because of the small sample).
GPi cGMP
Deep brain stimulation produced a clear cut increase of cGMP 
levels (Table 1, Figure 2; average +606.2%, ANOVA main effect 
df = 2/18; ε = 0.515; df = 1.03/9.28; F = 20.56, p = 0.00002). Post hoc 
Scheffé test showed: basal vs DBS p = 0.000047; DBS vs recovery 
p = 0.000489. Friedman ANOVA followed by Wilcoxon confirmed 
these significances.
To note, the quantification of intra-GPi GABA, in this series of 
patients, was not performed since already investigated in our semi-
nal paper (Fedele et al., 2001); to mention, no significant change of 
GPi GABA was observed even following prolonged and clinically 
effective stimulation periods.
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and subthalamotomy suggested that high-frequency stimulation 
acted through a sort of functional ablation. The so-called “suppres-
sion hypothesis” (Benazzouz et al., 2000; Filali et al., 2004) insisted 
on firing silencing as the major DBS mechanism of action. Whilst 
such hypothesis gained credit inside STN (Filali et al., 2004), since 
each stimulus was in fact followed by a no-spiking time window, it 
was abundantly challenged by evidence collected in target stations 
(GPi/SNr) in primates and humans (see later).
To further complicate this issue, studies performed in rodent’s 
models of PD have shown quite conflicting data. Some groups 
have described a prevalent inhibition of SNr during STN-DBS, 
through GABA release eventually from GP, utilizing stimulation 
period abundantly sufficient to induce behavioral changes (up to 
1 h, Windels et al., 2003, 2005). Others, by means of multi-chan-
nel recordings in freely moving rats described the prevalence of a 
mixed response (“nearly equal numbers of excitatory and inhibitory 
responses were found in the GP and SNr”) and a relevant decrease 
of burst firing (Shi et al., 2006).
Motor thalaMus GaBa
STN-DBS produced a significant decrease in GABA level during 
stimulation (Table 1, Figure 2; average −31.1%; ANOVA main effect 
df = 2/18; ε = 0.784; df = 1.56/14.11, F = 11.83, p = 0.000523; 0.0016 
Greenhouse–Geisser  correction).  Post  hoc  Scheffé  test  showed: 
basal vs DBS p = 0.000783; DBS vs recovery p = 0.00413. Friedman 
ANOVA followed by Wilcoxon confirmed these levels of significance.
PutaMen cGMP
DBS produced a clear cut increase of PUT cGMP (n = 6), as already 
partially described (Stefani et al., 2006). The average increase was 
220%; the mean value was significantly higher (Wilcoxon test, Z = 2.52, 
p < 0.05) than the mean basal and recovery. In each patient, the rise of 
PUT cGMP was clear from the section following DBS-ON (Figure 2).
dIscussIon
In the classical BG model (Albin et al., 1989; DeLong, 1990), PD aki-
nesia results from an imbalance between indirect and direct path-
ways and correlates with an overactivity of the STN and the GPi. 
FiGURe 1 | Trajectories of the multi-electrodes-probes holders aimed at the 
STN-VA (A) and at the PUT-GPi (B). Each section shows representative 
diagrams of the utilized multi-electrode holder (top) and, at the bottom, two 
different partially superimposed sections of atlas (note the hand leafing the 
superior section). The left bottom panel shows coronal atlas section at 1.5 mm 
posterior to the inter-commissural midline (Fp 1.5, STN target) and at 4 mm 
anterior to the inter-commissural midline (Fa 4.0 VA target). The right bottom 
panel illustrates coronal atlas section at 2 mm anterior to the inter-commissural 
midline (Fa 2.0 GPi target) and at 7 .5 mm anterior to the inter-commissural 
midline (Fa 7 .5 PUT target). To reach STN passing through the VA, the central 
electrode of the multi-electrode holder (A) was aimed at a target at 8.5 mm of 
laterality, −4 mm with respect to the AC-PC plane, and at the mid point of the 
AC-PC line. The trajectory had an angle of 70°–75° in sagittal plane and of 
85°–90° in the coronal plane. The more lateral electrode of the multi-electrode 
holder [electrode A in (A)] was at 3.5 mm of laterality from the central one. This 
laterality allowed to reach a target at 12.0 mm of laterality from the mid line, 
which is the usual location of the STN target. On the contrary, the electrode B 
trajectory was 1.5 mm more medial than the central one and 2 mm more 
anterior. The probe membrane (4 mm length) was positioned between 11.0 and 
7 .0 mm above the target (+7 to +3 mm above the inter-commissural plane), along 
the trajectory of electrode B. Given the angle in the sagittal planes (70°–75°), the 
trajectory had a laterality of 7 .0 mm and, at the level of +7 to +3 mm above the 
inter-commissural plane, its antero-posterior position was between +6.0 and 
+4.0 mm with respect to the midpoint of the inter-commissural line, 
corresponding to the center of VA. After electrophysiological identification of the 
targets, the recording electrode in the GPi was replaced by a microdialysis probe 
[trajectory C in (B)]. A second probe was positioned in trajectory D, at the level 
of PUT [D in (B)], utilizing the antero-lateral hole of the multi-electrode holder 
according to the coronal angle used. Probe membrane was positioned at a 
laterality between 22.5 and 25.0 mm, a depth of +9.0 with respect to the 
inter-commissural plane, and between +4.8 and +7 .5 mm anterior to the 
midpoint of the inter-commissural line. Probes and stimulating electrode real 
positions were verified during surgery by X-ray in antero-posterior and 
latero-lateral projection.
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gabamimetic muscimol and replicated by intra-GP injection of 
the D2-antagonist haloperidol. Overall, these findings reinforce 
the idea that fast motor commands are transferred through the 
hyper-direct pathway, alongside or in combination with changes 
of striatofugal networks.
Second, experiments performed with optogenetics supported the 
relevant role sub-served by cortico-STN pathway, if, as Gradinaru 
suggested, behaviorally effective high-frequency DBS was associated 
with a clear activation of axons impinging STN neurons.
Third,  a  renewed  interest  in  non-cortical  excitatory  inputs 
to striatum (that is, thalamic outputs impinging on cholinergic 
interneurons) forces us to consider the possibility that the thalamo-
putaminal-pallidal loop plays a relevant role, as far as salient stimuli 
may perturb motor planning.
Overall, these considerations suggest that over-emphasis on fine 
details of circuitry may obscure a bigger picture.
The decrease of GABA concentration inside the motor thalamus 
(VA), during effective STN-DBS, reconciles with some aspects of the 
old model of BG function (Albin et al., 1989; DeLong, 1990). The 
GABA levels’ reduction, in VA, would dis-inhibit VA firing activ-
ity and possibly influence its patterning; reduced bursting and/or 
suppressed oscillatory activity are the most likely results, as already 
inferred (Guo et al., 2008). The precise firing properties of human 
VA/VL during effective STN-DBS are unknown (but see Kempf 
et al., 2009) and we did not perform multiple recording traces in 
human PD VA on ethical grounds, since the latter is not a target of 
stimulation in PD (whilst appropriate in some pharmaco-resistant 
epileptic patients, Hodaie et al., 2006). However, previous studies 
may help the interpretation.
On one hand, GPi-DBS reduced VA/VL firing activity in normal 
monkeys (Anderson et al., 2003); on the other, Vitek described 
a mixed response in MPTP-intoxicated primates. Although the 
“lack of a significant reduction in the mean rate of discharge” was 
attributed to the early DBS-induced brisk excitation peak, there 
is no doubt that the “the most relevant changes due to effective 
DBS-STN was a dramatic modification of the PSTH, hence of 
patterning,” characterized by “reduced bursting and more regular 
spike trains in thalamus” (Xu et al., 2008). Similarly, the Rubin and 
Terman (2004) model emphasized that STN-DBS, in order to be 
beneficial, induced clustered firing patterns in GPi, whose clear 
consequence is a regularization of VA discharge (more tonic, no 
pausing; see Figure 3).
As pointed out by Guo, STN-DBS altered Parkinsonian GPi 
activity in a way that may improve thalamocortical relay fidel-
ity (Rubin and Terman, 2004; Guo et al., 2008). In this context, 
the reduced GABA levels that we observed would impede pro-
longed post-spiking after hyper-polarization, and favors a more 
regular pattern of neuronal activity (in striking contrast with the 
GABAergic and dopaminergic modulation of delta waves in reticu-
lar nuclei, i.e., Urbano et al., 2009).
The VA/VL nuclei complex represents the crucial link between 
BG outputs and specific cortical areas (Blandini et al., 2000; Obeso 
et al., 2008). Therefore, once VA-VL is modulated by STN-DBS (as 
a consequence of reduced GABA release), immediate changes in 
thalamocortical transmission would occur. Imaging studies have 
demonstrated a re-activation of fronto-temporo-parietal cortex at 
In humans and non-human primates (NHP), we and others have 
documented that the clinical benefit may parallel an increased – and 
not decreased – GPi and SNr discharge rate and, more importantly, 
a dramatic modulation of their pattern of activity (Hashimoto et al., 
2003; Galati et al., 2006). Accordingly, as detailed since our pioneer-
ing papers in the GPi of PD patients, DBS failed to affect amino 
acids levels (no GABA decrease, in particular, Fedele et al., 2001) 
but caused a large increment of the cGMP title (Stefani et al., 2005).
Whereas  the  negligible  modification  of  glutamate  could  be 
attributable to lack of sensitivity of the technique, the lack of GABA 
concentration change suggests that a strong dampening of excit-
ability (in GPi/SNr) is not likely to occur during clinically relevant 
STN-DBS (whilst it is the rule under apomorphine! i.e., Stefani 
et al., 1997, 1999).
Investigations  performed  in  MPTP-treated  primates  sound 
more in agreement with our central hypotheses. The GPi neuronal 
activity recorded during efficacious STN-DBS is indeed more regu-
lar, being time locked to the stimulus pulse, and had less bursting 
activity (Hashimoto et al., 2003; Hahn et al., 2008).
The mismatch between 6-OHDA rodents and humans is puz-
zling but highlights once more that the abrupt dopamine denerva-
tion induced by standard 6-OHDA intoxication – weeks/months, in 
rats – is not fully appropriate for human PD. This may reflect the 
overwhelming role played by some compensatory mechanisms in 
the non-human models, at replicating most changes of the progres-
sively developing disease in humans. By taking into account data 
collected in human and non-human primates, it is reasonable to 
speculate that some features of the standard model, if centered 
on the putative hyperactivity of GPi/SNr as key factor underlying 
Parkinsonian OFF-state, are wrong.
At least three recent observations modify further our perception 
of BG functional circuitry. First, Brown and colleagues showed 
abundant evidence for the behavioral role of specific band fre-
quencies (i.e., alpha rhythms for attention, beta for motor per-
formance) linking cortex, STN and GPi. Even “acute” dopamine 
denervation (our TTX-mediated inactivation of the medial fore-
brain bundle, Galati et al., 2009, 2010) potentiated a synchro-
nized low frequency discharge coupling STN-GPi to cortex. This 
pathological synergy between cortex and BG, in our hands, was 
Table 1 | The table synthesizes the more relevant data detected by 
microdialysis samples during efficacious STN-DBS.
  Basal  STN-DBS  Recovery
cGMP-GPi (fmol/50 μL, n = 10)
Mean  1.6  9.7  3.1
SD  0.5  5.7  1.6
GABA-VA (pmol/50 μL, n = 6)
Mean  4.5  3.1  4.2
SD  0.5  0.8  0.9
cGMP-PUT (fmol/50 μL, n = 6)
Mean  1.45  3.2  1.8
SD  0.1  1.3  0.3
UPDRS section III (selected items)
Mean  8.4  5.5  8.2
SD  1.0  1.4  0.9
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before, during and after STN-DBS. Microdialysis probes were infused (5 μl/min) 
for stabilization (90 min). During stabilization, the permanent stimulating 
electrode (Medtronic mod 3389) was implanted in ipsilateral STN. Following STN 
electrode insertion and probe stabilization, collection of 10-min fraction samples 
(50 μl each) started. The first five fractions of each probe were utilized for basal 
evaluation either for GABA (VA probe, scale on the left y axis in pmol/50 μl) or for 
cGMP (PUT and GPi probes, scale on the left y axis in fmol/50 μl). Basal values 
are in the white area at the left of the shaded area. Values represent mean ± SD. 
After Medtronic mod 3389 electrode implantation, monopolar STN-DBS was 
then switched on by a Medtronic external device Model 3625 at a rate between 
130 and 160 Hz, anodal pulse of 60–90 μs, and voltage progressively increased by 
steps of 0.1 V up to the appearance of side effects (paresthesia or dystonia or 
myoclonus). Voltage was never above 3.0 V. Voltage stimulation was then 
decreased by 10% or more to obtain disappearance of clinical side effects. 
Clinical assessment started with microdialysis basal fraction collection. Clinical 
changes, contra lateral upper limb rigidity and akinesia were continuously 
assessed by an expert neurologist utilizing selected items of UPDRS (rigidity 0–4, 
finger tapping 0–4, hand movement 0–4; total = 0 corresponds to “normal, ” 12 
maximum score; scale on the right y axis in each frame), while remaining blind to 
the stimulus intensity between 0 and 3 V. The patient was unaware of the time of 
stimulus ON. In all the reported patients, an improvement of the sum of rigidity 
and akinesia of the upper contralateral arm of more than 30% was achieved 
without side effects within the first 10 min of stimulation at an intensity ranging 
between 2 and 3 V, while the first fraction during stimulation was collected. 
STN-DBS intensity was kept constant thereafter and 10-min fractions were 
collected during 1 h of stimulation while clinical efficacy was continuously 
monitored to ensure persistence of the clinical effects. Clinical scores and 
biochemical parameters are reported every 10 min. After 1 h, STN-DBS was 
discontinued and 10-min fractions were collected for one additional hour.
rest after effective STN-DBS (Hilker et al., 2004, but see Hershey 
et al., 2003). Even in case STN-DBS apparently decreased rCBF 
in the motor cortex at rest – implying a reduction of abnormal 
overactivity in the motor system – this allowed selective cortical re-
activation during active movement (Limousin et al., 1997; Payoux 
et al., 2004).
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microdialysis in the surgery room; it represents a time-consuming 
approach, and ethical observations demand not to stress any patient 
if an immediate benefit is not perceived. Second, the “double-target” 
strategy has lost many fans, nowadays, making unlikely the simul-
taneous insertion of multiple electrodes in different BG stations. 
In other words, very few groups are still advocating these methods 
(but see Kilpatrick et al., 2010).
Yet, as we have tried to present in this paper, microdialysis had 
the profound merit to clarify the limitations of a dogmatic box 
and arrow cartoon scheme on BG circuitry, if merely intended as 
a simplistic balancing between overactive structures of the indirect 
pathway and facilitating structures governing the direct pathway. 
In this content, Figure 3 aims at presenting, albeit speculatively, 
findings derived from our last decade studies, again illustrating 
the importance to match functional recordings with alterations 
of endogenous transmitters.
In the next future, it is likely that newly developing approaches, 
centered on functional biochemistry, will be applied to PD patients. 
In particular, new electrochemical techniques, including fast-scan 
cyclic voltammetry (FSCV; Agnesi et al., 2009), should allow to 
detect changes that are happening on a second-to-second time scale 
(also feasible for chronically used implanted recordings, as would 
be required for DBS feedback).
As a matter of fact, the Wireless Instantaneous Neurochemical 
Concentration Sensor (WINCS) is currently a research device, 
whose resolution was established on pig brain, but it is designed 
for human use and is capable of in vivo FSCV plus amperometry, 
sampling at sub-second time resolution (Agnesi et al., 2009; Van 
Gompel et al., 2010). It promises, for instance, to assess if and to 
what extent effective STN-DBS is actually changing the tonic/pha-
sic release of endogenous dopamine in human caudate/putamen 
(Covey and Garris, 2009; Van Gompel et al., 2010).
Overall, the implementation of these techniques will represent 
a real upgrade of our understanding of STN-DBS mechanisms of 
actions and, more critically, of our knowledge around the acute 
processes which rule clinical transitions in different extrapyramidal 
disorders.
conclusIon
Much recent literature has attempted to explain the mechanisms 
of  action  of  DBS.  Using  optogenetic  techniques,  Gradinaru 
et al. (2009) have suggested that the more critical behaviorally 
related change promoted by high-frequency STN stimulation, 
in 6-OHDA rodents, is the direct activation of cortical axons to 
STN. This may stimulate new interest into DBS-mediated modu-
lation of corticofugal pathways (i.e., the increase of putaminal 
cGMP that we have described), as inferred in early 2000s (Ashby 
et al., 2001).
On the other hand, in a brain slice preparation thalamostriatal 
axons exerted a marked modulation of firing in striatal cholinergic 
interneurons (in response to salient stimuli; Ding et al., 2010). 
This pathway would affect cortical input to medium spiny neu-
ron (MSN), enhancing the postsynaptic responsiveness of striat-
opallidal MSNs, which strongly influence motor programming. 
This suggests that interpretation of the BG circuitry in terms of 
The two main effects induced by STN-DBS, as here described 
(increased cGMP in GPi and lower GABA in VA) seem in con-
flict each other, but do not necessarily correlate. STN-DBS indeed 
reverberate on multiple sites, including VTA and PPN extended 
area (Stefani et al., 2007), which in turn affect ascending pathways 
toward thalamus. In other words, the proteiform response to DBS 
on distant structures might overcome the strict boundaries of the 
direct/indirect pathway scheme.
Besides, the data concerning the DBS-mediated increase, inside 
PUT, of cGMP appear, in this context, as a further confirmation of 
the reinstalled physiological BG-cortex and cortico-BG transmis-
sion (otherwise impaired by PD OFF-state).
functIonal IMPlIcatIons
We are showing a consistent, DBS-mediated GABA decline in the 
motor thalamus, which may associate with simultaneous increase 
of GPi and PUT cGMP.
A  number  of  investigations  from  multiple  disciplines  are 
supporting the hypothesis that stimulation-induced modula-
tion of pathological network activity represents the most likely 
mechanism of DBS (Brown, 2003). However, successful theories 
founded on the rebalancing of beta/gamma band frequencies 
should not discard, in agreement with recent conclusions by 
Johnson, Vitek,  and  McIntyre  (“DBS  improves  Parkinsonian 
motor  symptoms  by  inducing  global  changes  in  firing  pat-
tern  and  rate  along  the  pallidothalamocortical  sensorimotor 
circuit,” Johnson et al., 2009), the central result of this report, 
that the motor thalamus is the critical station where efficacious 
re-  modulation (electrical or chemical) of pathological outputs 
promotes good therapeutic outcomes.
FiGURe 3 | Shown is an hypothetical scheme which infers, based upon 
our microdialysis data, the possible scenario driven by DBS on 
BG-cortical transmission. The clinical transition OFF–ON during effective 
STN-DBS is associated with increased cGMP in GPi and reduced GABA in GPi 
(this paper and Stefani et al., 1999, 2002). These data might correlate with 
clear changes of firing pattern in VA (from “bursty” – A2 – to regular – B2); in 
GPi, the large increase of cGMP level is in accordance with the increased 
firing activity (from A1 to B1) as described in seminal papers (Hashimoto et al., 
2003; Galati et al., 2006; Guo et al., 2008).
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